HOME >> MEDICINE >> NEWS
New study suggests that tamoxifen does not adversely impact brain chemistry

Torrance, Calif. (April 11, 2002) Surprising results from a new study may quell concerns about the safety of using tamoxifen to reduce breast cancer risk in elderly women, suggesting that both tamoxifen and estrogen have similar effects on the brain. The study was conducted at Harbor-UCLA Research & Education Institute (REI) in Torrance, California by research collaborators Rowan Chlebowski, M.D., Ph.D. and Thomas Ernst, Ph.D. and Linda Chang, M.D., of Brookhaven National Laboratory in New York. The findings will be published in the April 17 issue of the Journal of the National Cancer Institute and promise to advance breast cancer risk reduction as an achievable medical objective in the near future.

Based on the increase in hot flashes that are associated with tamoxifen, it has been suggested that the drug blocks the potentially favorable effects of estrogen on the brain. Weve found just the opposite, said Dr. Chlebowski. We were surprised to find similarities between the two groups in that women who have been treated with tamoxifen had lower levels of myo-inositol, a chemical that increases in response to brain injury. Women who took estrogen also had lower levels of the chemical, he added.

This study is unique in that it uses Proton Magnetic Resonance Spectroscopy (MRS), a non-radioactive brain imaging technique to measure levels of cerebral metabolites in this case myo-inositol to predict the effects of tamoxifen. The study compared levels of myo-inositol in 16 breast cancer survivors who had been treated with tamoxifen for at least two years, 27 healthy women who had been treated with preventive estrogen replacement therapy for at least two years, and 33 healthy women who had not received any treatment.

Study participants were between the ages of 65 and 80 who did not have any neurologic diseases. Dr. Chlebowski and his collaborators concluded that both tamoxifen and estrogen may be neuroprotective and may have favorable
'"/>

Contact: Barbara Kerr
bkerr@rei.edu
310-222-2820
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
16-Apr-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. UMaine study looks at infants and chronic nighttime crying
3. Chronic pain treatments more effective when taken together, new study shows
4. UNC study: Most N.C. family practitioners engage in unrecognized community service
5. New study in Nature demonstrates protection against cell death during heart attack
6. UCSF study offers insight into human circadian rhythms
7. International breast cancer prevention study launches in the United States and Canada
8. UW study shows blacks and Latinos are more satisfied with physicians of the same race
9. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
10. Advertising by academic medical centers may risk eroding public trust, says study
11. Fat may promote inflammation, new study suggests

Post Your Comments:
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... Wojo Nutrition announces Abe’s ... its healthiest, will carry Wojo Nutrition's lines of single ... Nutrition, they’ve launched a revolution in the vitamin industry ... meet their multifaceted goals. Their line of single serving ... has been specially formulated to be as unique as ...
(Date:4/21/2015)... has released a new blog post explaining the ... , Comprehensive auto insurance is a complex policy ... limit can also be high and the premiums are ... against fire damage, vandalism, theft and from many other ... and it can help drivers find the right type ...
(Date:4/21/2015)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is hosting a complimentary webinar on April ... benefits of offering this service to employees. , As ... their healthcare, it is critical that they have access ... their health benefits. Health advocates can play a significant ...
Breaking Medicine News(10 mins):Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2Health News:Health Advocate Webinar Discusses Benefits of Health Advocacy 2
(Date:4/21/2015)... SPRING, Md. , April 21, 2015 /PRNewswire-USNewswire/ ... told the U.S. Food and Drug Administration that ... worked effectively for the last 25 years to ... to safe homeopathic medicines. AAHP, the industry,s trade ... and consumers of homeopathic medicines to engage in ...
(Date:4/21/2015)... 21, 2015 Delcath Systems, Inc. (NASDAQ: ... Trial Authorizations (CTAs) filed with the U.K.,s ... and Germany,s Federal Institute for ... the Company,s global Phase 2 program for the treatment ... or HCC), to include a cohort of patients with ...
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
Breaking Medicine Technology:Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5
Cached News: